Andrew Cox, Pharm.D., MBA

A new study highlighted the potential benefits of RSV vaccination, suggesting that the vaccines could provide both individual and societal cost savings.

A review of skeletal muscle relaxants shows that they don't work for pain from osteoarthritis, neuropathic pain and other conditions. Some see an opportunity for more tailored therapeutic strategies, improving patient outcomes.

Most people haven’t heard of the condition, but Friedreich’s ataxia is getting more attention because of a new treatment and a large number of clinical trials enrolling people with the condition.

Results looking at the first season of RSV use shows that it is 75% effective at preventing RSV-associated hospitalizations in those 60 and older.

The future of pain medicine is characterized by treatments and technologies — including virtual reality, AI, wearable tech and psychedelics — that promise to significantly enhance patient care.

Genetic and biochemical testing are crucial for improving outcomes for patients with Friedreich ataxia, according to speakers at a symposium at the European Association of Neurology Congress.

A systemic review of corticosteroid studies finds that their anti-inflammatory effects can be beneficial in addressing peripheral injuries and as a adjuvant for treating the associated pain.

Researchers are studying how leukocyte telomere length may be associated with the progression of Friedreich's ataxia.

The approval of Skyclarys underscored the importance of sensitive outcome measures, say authors.

The two clinical trials will enroll patients recovering from surgical procedures.

The company's vaccine consists of an mRNA sequence encoding a stabilized prefusion F glycoprotein.

The interplay between chronic pain and HIV can complicate treatment regimens, negatively impact functional abilities, and diminish overall quality of life for affected individuals.

Existing treatments for FDRA are limited and often fail to effectively address the root causes of the disease or manage its neurological symptoms.

The management of pain in older adults with cancer remains a significant public health concern and an unmet medical need, particularly in rural areas. This demographic often encounters specific challenges, such as limited access to healthcare services, hesitancy to talk about pain, and misunderstandings about pain management.

Given the lack of approved treatments for FA cardiomyopathy, LX2006's potential could represent a breakthrough for patients suffering from a disease characterized by severe cardiac complications.

This past May, Larimar Therapeutics, a clinical-stage biotechnology company focused on developing treatments for rare diseases, announced that its lead compound for Friedreich's Ataxia, Nomlabofusp, would participate in the START pilot program. Nomlabofusp is one of the three Center for Drug Evaluation and Research programs and one of the six programs selected by the FDA.

Shoulder pain can originate from various sources, such as osteoarthritis, post-operative discomfort, musculoskeletal injuries like a torn labrum, neuralgia and paralytic shoulder injury. Recent research has shown that PNS can effectively manage chronic and acute pain.

Like fish oils, krill oil also contains omega-3 fatty acids and has a comparably better bioavailability than fish oil. Additionally, krill oil contains a potent antioxidant known as astaxanthin, which may reduce inflammation resulting from free radicals.

Over the years, the landscape of pain management has witnessed significant shifts as new research emerges and healthcare practices adapt to changing needs.

Previous studies on lipid levels and disease activity are inconsistent, and a causal relationship between lipid levels and IBD remains dubious.

Developed by Vertex Pharmaceuticals, suzetrigine is a promising new class of pain medicine that has been gaining attention for its innovative mechanism of action and reported efficacy; suzetrigine might offer hope for those struggling with acute pain issues who want to avoid opioids and NSAIDs.

Tremfya is an interleukin (IL)-23 and CD64-inhibiting monoclonal antibody. The FDA approved it in 2017 as a moderate to severe plaque psoriasis treatment. It has since been approved to treat psoriatic arthritis.

A study published in Nature Immunology focused on understanding the origins of stem-like T cells in ulcerative colitis patients. By analyzing colon tissue samples from human patients, researchers found a significant population of stem-like T cells in inflamed regions of the large intestine compared to healthy individuals.

In a randomized clinical trial, the effectiveness of a stepped-care model for delivering palliative care to patients with advanced lung cancer was evaluated.

Researchers evaluated the association between body composition from readouts generated by cross-sectional imaging and oncologic outcomes in patients with advanced or metastatic NSCLC treated with systemic immunotherapy.

The study evaluated the efficacy and safety of Dato-DXd compared to docetaxel in adult patients with locally advanced or metastatic NSCLC with and without actionable genomic alterations who require systemic therapy following prior treatment.

Results point to the benefit of adding Darzalex (daratumumab) to Velcade-Revlimid-dexamethasone triplet therpay, although serious side effects seem be slightly more common when Darzalex is added.

A combination of navitoclax and Jakafi (ruxolitinib) achieved spleen volume reduction, although adverse events led to some dose modifications and treatment interruptions.